<?xml version="1.0" encoding="UTF-8"?>
<p>A key secondary endpoint was OS. Other secondary endpoints included: disease‐specific efficacy endpoints; the type, incidence, severity, timing, seriousness and relatedness of AEs; corrected QT (QTc) interval; glasdegib PK; and mutational analyses. Exploratory endpoints included: CR in patients younger than 55 years and efficacy endpoints based on cytogenetic risk. For AML, cytogenetic risk was assessed using European Leukemia Net (ELN) Risk Criteria 2010.
 <xref rid="ajh25238-bib-0032" ref-type="ref">32</xref> For MDS, the International Prognostic Scoring System (IPSS) was used.
 <xref rid="ajh25238-bib-0033" ref-type="ref">33</xref>
</p>
